PATENT CLAIM ANALYSIS

Application Number: 16063047
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "001000"]

Abstract:
The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

Claim (Index 10):
The prophylactic and/or therapeutic agent for age-related macular degeneration according to  claim 9 , wherein the propionic acid-based nonsteroidal anti-inflammatory drug is at least one selected from the group consisting of zaltoprofen, oxaprozin, ibuprofen, flurbiprofen, tiaprofenic acid, and pharmaceutically acceptable salts thereof,\n the aminoaryl carboxylic acid-based nonsteroidal anti-inflammatory drug is at least one selected from the group consisting of flufenamic acid, mefenamic acid, and pharmaceutically acceptable salts thereof, the aryl acetic acid-based nonsteroidal anti-inflammatory drug is sulindac and/or a pharmaceutically acceptable salt thereof, the leukotriene receptor antagonist is at least one selected from the group consisting of zafirlukast, montelukast, pranlukast, and pharmaceutically acceptable salts thereof, and/or the chemical mediator release suppressor is amlexanox and/or a pharmaceutically acceptable salt thereof, the thromboxane A2 receptor antagonist is seratrodast and/or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 94.0
- Lexical Diversity: 2.0
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12382702', '10685705', '13698518', '10773446', '14415994']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7889080861924858
- 35 USC 102 Novelty (BERT): 0.5270330169511002
- Combined Prediction Score: 0.7627205792683472
- Mean Citation Score: 307.786744
- Max Citation Score: 317.071
- Similarity Product: 212.1543374125957

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test